Lipella Pharmaceuticals Common Stock Today
| LIPO Stock | 2.50 0.06 2.34% |
PerformanceWeak
| Odds Of DistressBelow Average
|
Lipella Pharmaceuticals is selling at 2.50 as of the 25th of March 2025; that is 2.34 percent decrease since the beginning of the trading day. The stock's open price was 2.56. Lipella Pharmaceuticals has about a 28 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of December 2022 | Category Healthcare | Classification Health Care |
Lipella Pharmaceuticals is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 1.21 M outstanding shares of which 216.18 K shares are now shorted by private and institutional investors with about 0.01 trading days to cover. More on Lipella Pharmaceuticals Common
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lipella Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman, CoFounder | Jonathan MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lipella Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lipella Pharmaceuticals' financial leverage. It provides some insight into what part of Lipella Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lipella Pharmaceuticals Common (LIPO) is traded on NASDAQ Exchange in USA. It is located in 7800 Susquehanna St., Pittsburgh, PA, United States, 15208 and employs 5 people. Lipella Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.57 M. Lipella Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.21 M outstanding shares of which 216.18 K shares are now shorted by private and institutional investors with about 0.01 trading days to cover.
Lipella Pharmaceuticals generates negative cash flow from operations
Check Lipella Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationLipella Pharmaceuticals Common holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Lipella Ownership Details
Lipella Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Virtu Financial Llc | 2024-12-31 | 13.3 K | |
| Mccormack Advisors International | 2024-12-31 | 125 | |
| Bank Of America Corp | 2024-12-31 | 7.0 | |
| Sabby Management Llc | 2024-09-30 | 0.0 | |
| Two Sigma Investments Llc | 2024-09-30 | 0.0 | |
| Ubs Group Ag | 2024-09-30 | 0.0 |
Lipella Pharmaceuticals Historical Income Statement
Lipella Stock Against Markets
Lipella Pharmaceuticals Corporate Executives
Elected by the shareholders, the Lipella Pharmaceuticals' board of directors comprises two types of representatives: Lipella Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipella. The board's role is to monitor Lipella Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lipella Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipella Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael MD | Chief CoFounder | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.88) | Revenue Per Share | Quarterly Revenue Growth 0.279 | Return On Assets | Return On Equity |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.